Key Highlights: CEPHEUS Trial SubQ Dara-VRd vs VRd in Transplant-Eligible or Transplant-Deferred NDMM

Opinion
Video

Panelists discuss how the CEPHEUS study comparing subcutaneous daratumumab plus VRd vs VRd alone in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) provides important insights into the role of quadruplet therapy in this specific population.

Video content above is prompted by the following:

  1. Let’s transition to patients with NDMM who are considered transplant ineligible or transplant deferred.
    1. Can you summarize the recent data from the CEPHEUS study evaluating subcutaneous daratumumab plus VRd vs VRd in transplant-ineligible NDMM?
Recent Videos
Two experts are featured in this series.
Two experts are featured in this series.
Two experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Two experts are featured in this series.
Two experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
From phase 3 trial updates to results on trispecific antibodies, ASH 2025 may feature a variety of practice-shifting presentations across multiple myeloma.

ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?

Russ Conroy
December 4th 2025
Article

From phase 3 trial updates to results on trispecific antibodies, ASH 2025 may feature a variety of practice-shifting presentations across multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Two belantamab mafodotin regimens have been approved in multiple myeloma despite the FDA’s ODAC committee voting against the proposed dosages due to ocular toxicities.

FDA Approves Belantamab Mafodotin in R/R Multiple Myeloma

Tim Cortese
October 23rd 2025
Article

Belantamab mafodotin has been approved for multiple myeloma, despite the FDA’s ODAC voting against the treatment due to ocular toxicities.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

The safety profile of venetoclax combined with bortezomib and dexamethasone was consistent with previously published results.

Venetoclax Combo Achieves Mixed Results in Relapsed/Refractory Multiple Myeloma

Tim Cortese
October 17th 2025
Article

Venetoclax with bortezomib and dexamethasone led to a median PFS of 23.4 months compared with 11.4 months with placebo in patients with R/R MM.

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma

Russ Conroy
October 16th 2025
Article

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.